| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.24 | 0.0004 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.22 | 0.0001 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.22 | 5e-09 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.21 | 0.0009 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.21 | 2e-08 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.19 | 6e-08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.19 | 4e-07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.18 | 0.006 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.17 | 0.01 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.1 |